FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jeffrey Schlom

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Physiology

Lymphocyte Activation

Co-author Network

Publications

TOP 3
Ngar-Yee Huen; Chiara Intrivici; Caroline Jochems; Tin-Lap Lee; Ravi A Madan; Alan Lap-Yin Pang; Owen M Rennert; Jeffrey Schlom; Vittore Cereda; Wai-Yee Chan; James L Gulley; Jo A Tucker; Matteo Vergati; Kwong-Yok Tsang
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Christopher T Campbell; James L Gulley; James W Hodge; Oyindasola Oyelaran; Jeffrey Schlom; Jeffrey C Gildersleeve
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Jianping Huang; Alessandra Jales; Caroline Jochems; Ravi A Madan; Austin Anderson; James L Gulley; Tara Talaie; Kwong Y Tsang; Jeffrey Schlom
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jeffrey Schlom (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ngar-Yee Huen; Chiara Intrivici; Caroline Jochems; Tin-Lap Lee; Ravi A Madan; Alan Lap-Yin Pang; Owen M Rennert; Jeffrey Schlom; Vittore Cereda; Wai-Yee Chan; James L Gulley; Jo A Tucker; Matteo Vergati; Kwong-Yok Tsang
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
International journal of cancer. Journal international du cancer 2013;133(2):373-82.
2013: Christopher T Campbell; James L Gulley; James W Hodge; Oyindasola Oyelaran; Jeffrey Schlom; Jeffrey C Gildersleeve
Serum antibodies to blood group A predict survival on PROSTVAC-VF.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1290-9.
2012: Jianping Huang; Alessandra Jales; Caroline Jochems; Ravi A Madan; Austin Anderson; James L Gulley; Tara Talaie; Kwong Y Tsang; Jeffrey Schlom
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood 2012;120(15):3030-8.
2012: M Kamrava; A Kaushal; A H Kesarwala; E Lita; Ravi A Madan; Diane J Poole; Jeffrey Schlom; S M Steinberg; K-Y Tsang; W Dahut; T Ferrara; James L Gulley
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate cancer and prostatic diseases 2012;15(3):289-95.
2012: Mario Roselli; Jeffrey Schlom; Antonella Spila; Kwong-Yok Tsang; Joanne Tucker; Raffaele Palmirotta; Jhessica Alessandroni; Leopoldo Costarelli; Romaine I Fernando; Fiorella Guadagni; Duane Hamilton; Bruce Huang; Mary Litzinger; Claudia Palena
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(14):3868-79.
2012: Ravi A Madan; Jeffrey Schlom; Marijo Bilusic; Christopher Heery; James L Gulley
Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
Seminars in oncology 2012;39(3):296-304.
2012: Jeffrey Schlom; James W Hodge
Introduction: Therapeutic cancer vaccines.
Seminars in oncology 2012;39(3):243-4.
2012: Shinji Takai; Benedetto Farsaci; Helen Sabzevari; Jeffrey Schlom; John W Greiner
Distinct effects of saracatinib on memory CD8+ T cell differentiation.
Journal of immunology (Baltimore, Md. : 1950) 2012;188(9):4323-33.
2012: Ravi A Madan; Mahsa Mohebtash; Howard L Parnes; Diane J Poole; Myrna Rauckhorst; Jeffrey Schlom; Seth M Steinberg; Kwong Y Tsang; Matteo Vergati; John J Wright; Philip M Arlen; William L Dahut; James L Gulley
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
The lancet oncology 2012;13(5):501-8.
2012: Jeffrey Schlom
Therapeutic cancer vaccines: current status and moving forward.
Journal of the National Cancer Institute 2012;104(8):599-613.
2012: Jeffrey Schlom
Recent advances in therapeutic cancer vaccines.
Cancer biotherapy & radiopharmaceuticals 2012;27(1):2-5.
2012: Adrian Bot; Dirk Brockstedt; Lisa H Butterfield; Andrew Cornforth; Richard Harrop; W Martin Kast; Richard Koya; Kim Margolin; Francesco Marincola; Candice McCoy; Graham Pawelec; Teresa Ramirez-Montagut; John Rothman; Jeffrey Schlom; Pramod Srivastava; Sarah Wallis; Steffen Walter; Ena Wang; Mark Ahn; Marnix Bosch; John Waslif
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.
Journal of translational medicine 2012;10():218.
2011: Mahsa Mohebtash; Mary Pazdur; Diane J Poole; Myrna Rauckhorst; Jeffrey Schlom; Seth M Steinberg; Kwong-Yok Tsang; Philip M Arlen; William L Dahut; Theresa Ferrara; Christopher R Heery; Ngar-Yee Huen; Caroline Jochems; Elizabeth C Jones; Jacquin Jones; Ravi A Madan; James L Gulley
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(22):7164-73.
2011: James L Gulley; Mitchell Kamrava; Ravi A Madan; Mahsa Mohebtash; Jeffrey Schlom; Kwong-Yok Tsang; Philip M Arlen; Kevin Camphausen; Deborah Citrin
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Expert opinion on biological therapy 2011;11(11):1409-18.
2011: Cecilia Larocca; Jeffrey Schlom
Viral vector-based therapeutic cancer vaccines.
Cancer journal (Sudbury, Mass.) 2011;17(5):359-71.
2011: Vittore Cereda; Maria Giovanna di Bari; James L Gulley; Ngar-Yee Huen; Chiara Intrivici; Caroline Jochems; Jeffrey Schlom; David Apelian; Matteo Vergati; Kwong Y Tsang
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
Vaccine 2011;29(31):4992-9.
2011: James L Gulley; Ravi A Madan; Jeffrey Schlom
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
Current oncology (Toronto, Ont.) 2011;18(3):e150-7.
2011: Caroline Jochems; Jeffrey Schlom
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.
Experimental biology and medicine (Maywood, N.J.) 2011;236(5):567-79.
2011: Claudia Palena; Romaine I Fernando; Mary T Litzinger; Duane H Hamilton; Bruce Huang; Jeffrey Schlom
Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.
Experimental biology and medicine (Maywood, N.J.) 2011;236(5):537-45.
2011: Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong-Yok Tsang
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer immunology, immunotherapy : CII 2011;60(2):197-206.
2011: Matteo Vergati; Jeffrey Schlom; Kwong-Yok Tsang
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring.
Journal of biomedicine & biotechnology 2011;2011():182413.
2011: Heath A Smith; Brett B Maricque; John Eberhardt; Benjamin Petersen; James L Gulley; Jeffrey Schlom; Douglas G McNeel
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
Journal of biomedicine & biotechnology 2011;2011():454861.
2011: Michael J Heffernan; David A Zaharoff; Jonathan K Fallon; Jeffrey Schlom; John W Greiner
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.
Biomaterials 2011;32(3):926-32.
2010: Mary Litzinger; Kenneth A Foon; Kwong-Yok Tsang; Jeffrey Schlom; Claudia Palena
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Leukemia research 2010;34(10):1351-7.
2010: Benedetto Farsaci; Helen Sabzevari; Jack P Higgins; Maria Giovanna Di Bari; Shinji Takai; Jeffrey Schlom; James W Hodge
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
International journal of cancer. Journal international du cancer 2010;127(7):1603-13.
2010: Jeffrey Schlom
The MUC1-C oncoprotein as a target in hematologic malignancies.
Cancer biology & therapy 2010;10(5):492-4.
2010: David A Zaharoff; Kenneth W Hance; Connie J Rogers; Jeffrey Schlom; John W Greiner
Intratumoral immunotherapy of established solid tumors with chitosan/IL-12.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(7):697-705.
2010: Nancy J Nesslinger; Alvin Ng; Kwong-Yok Tsang; Theresa Ferrara; Jeffrey Schlom; James L Gulley; Brad H Nelson
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(15):4046-56.
2010: Laura Masuelli; Laura Marzocchella; Chiara Focaccetti; Florigio Lista; Alessandra Nardi; Antonio Scardino; Maurizio Mattei; Mario Turriziani; Mauro Modesti; Guido Forni; Jeffrey Schlom; Andrea Modesti; Roberto Bei
Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
Cancer immunology, immunotherapy : CII 2010;59(8):1247-58.
2010: Julia Rotow; Sofia R Gameiro; Ravi A Madan; James L Gulley; Jeffrey Schlom; James W Hodge
Vaccines as monotherapy and in combination therapy for prostate cancer.
Clinical and translational science 2010;3(3):116-22.
2010: James L Gulley; Philip M Arlen; Ravi A Madan; Kwong-Yok Tsang; Mary P Pazdur; Lisa Skarupa; Jacquin L Jones; Diane J Poole; Jack P Higgins; James W Hodge; Vittore Cereda; Matteo Vergati; Seth M Steinberg; Susan Halabi; Elizabeth Jones; Clara Chen; Howard Parnes; John J Wright; William L Dahut; Jeffrey Schlom
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer immunology, immunotherapy : CII 2010;59(5):663-74.
2010: Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(7):1099-105.
2010: Amanda L Boehm; Jack Higgins; Alex Franzusoff; Jeffrey Schlom; James W Hodge
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
Cancer immunology, immunotherapy : CII 2010;59(3):397-408.
2010: Romaine I Fernando; Mary Litzinger; Paola Trono; Duane H Hamilton; Jeffrey Schlom; Claudia Palena
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.
The Journal of clinical investigation 2010;120(2):533-44.
2010: Matteo Vergati; Chiara Intrivici; Ngar-Yee Huen; Jeffrey Schlom; Kwong-Yok Tsang
Strategies for cancer vaccine development.
Journal of biomedicine & biotechnology 2010;2010():.
2010: Claudia Palena; Jeffrey Schlom
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
Journal of biomedicine & biotechnology 2010;2010():380697.
2010: Ravi A Madan; Mahsa Mohebtash; Jeffrey Schlom; James L Gulley
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
Expert opinion on biological therapy 2010;10(1):19-28.
2010: Vittore Cereda; Diane J Poole; Claudia Palena; Sudipto Das; Tapan K Bera; Cinzia Remondo; James L Gulley; Philip M Arlen; Junko Yokokawa; Ira Pastan; Jeffrey Schlom; Kwong-Yok Tsang
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer immunology, immunotherapy : CII 2010;59(1):63-71.
2009: Maria Giovanna di Bari; M E Christine Lutsiak; Shinji Takai; Sven Mostböck; Benedetto Farsaci; Roshanak Tolouei Semnani; Lalage M Wakefield; Jeffrey Schlom; Helen Sabzevari
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.
Cancer immunology, immunotherapy : CII 2009;58(11):1809-18.
2009: David A Zaharoff; Benjamin S Hoffman; H Brooks Hooper; Compton J Benjamin; Kiranpreet K Khurana; Kenneth W Hance; Connie J Rogers; Peter A Pinto; Jeffrey Schlom; John W Greiner
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.
Cancer research 2009;69(15):6192-9.
2009: James W Hodge; Jack Higgins; Jeffrey Schlom
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Vaccine 2009;27(33):4475-82.
2009: Mary Litzinger; Kenneth A Foon; Helen Sabzevari; Kwong-Yok Tsang; Jeffrey Schlom; Claudia Palena
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Cancer immunology, immunotherapy : CII 2009;58(6):955-65.
2009: Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2387-96.
2009: Sixun Yang; Jeffrey Schlom
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.
Cancer immunology, immunotherapy : CII 2009;58(4):503-15.
2009: Cinzia Remondo; Vittore Cereda; Sven Mostböck; Helen Sabzevari; Alex Franzusoff; Jeffrey Schlom; Kwong-Y Tsang
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.
Vaccine 2009;27(7):987-94.
2008: Connie J Rogers; David A Zaharoff; Kenneth W Hance; Susan N Perkins; Stephen D Hursting; Jeffrey Schlom; John W Greiner
Exercise enhances vaccine-induced antigen-specific T cell responses.
Vaccine 2008;26(42):5407-15.
2008: Martin A Cheever; Jeffrey Schlom; Louis M Weiner; H Kim Lyerly; Mary L Disis; Addison Greenwood; Oren Grad; William G Nelson
Translational Research Working Group developmental pathway for immune response modifiers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5692-9.
2008: Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin A. Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5284-91.
2008: Mala Chakraborty; Alexander Gelbard; Jorge Carrasquillo; Sarah Yu; Marcelo Mamede; Chang H Paik; Kevin A. Camphausen; Jeffrey Schlom; James W Hodge
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
Cancer immunology, immunotherapy : CII 2008;57(8):1173-83.
2008: Ravi A Madan; James L Gulley; Jeffrey Schlom; Seth M Steinberg; David J Liewehr; William L Dahut; Philip M Arlen
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4526-31.
2008: Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4316-25.
2008: Mala Chakraborty; Elizabeth K Wansley; Jorge Carrasquillo; Sarah Yu; Chang H Paik; Kevin A. Camphausen; Michael D Becker; William F Goeckeler; Jeffrey Schlom; James W Hodge
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4241-9.
2008: Charlie T Garnett; Jeffrey Schlom; James W Hodge
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3536-44.
2008: James L Gulley; Philip M Arlen; Kwong-Yok Tsang; Junko Yokokawa; Claudia Palena; Diane J Poole; Cinzia Remondo; Vittore Cereda; Jacquin L Jones; Mary Pazdur; Jack P Higgins; James W Hodge; Seth M Steinberg; Herb Kotz; William L Dahut; Jeffrey Schlom
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3060-9.
2008: M E Christine Lutsiak; Yutaka Tagaya; Anthony J Adams; Jeffrey Schlom; Helen Sabzevari
Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):5871-81.
2008: Jeffrey Schlom; James L Gulley; Philip M Arlen
Paradigm shifts in cancer vaccine therapy.
Experimental biology and medicine (Maywood, N.J.) 2008;233(5):522-34.
2008: Sven Mostböck; M E Christine Lutsiak; Diane E Milenic; Kwamena Baidoo; Jeffrey Schlom; Helen Sabzevari
IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(7):5118-29.
2008: Junko Yokokawa; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Jeffrey Schlom; Kwong-Yok Tsang
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1032-40.
2008: Hasan Zeytin; Eva Reali; David A Zaharoff; Connie J Rogers; Jeffrey Schlom; John W Greiner
Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(2):73-87.
2008: Michael B Bernstein; Mala Chakraborty; Elizabeth K Wansley; Zhimin Guo; Alex Franzusoff; Sven Mostböck; Helen Sabzevari; Jeffrey Schlom; James W Hodge
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
Vaccine 2008;26(4):509-21.
2008: Connie J Rogers; David Berrigan; David A Zaharoff; Kenneth W Hance; Arti C Patel; Susan N Perkins; Jeffrey Schlom; John W Greiner; Stephen D Hursting
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.
The Journal of nutrition 2008;138(1):115-22.
2007: David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Chitosan solution enhances the immunoadjuvant properties of GM-CSF.
Vaccine 2007;25(52):8673-86.
2007: Chie Kudo-Saito; Charlie T Garnett; Elizabeth K Wansley; Jeffrey Schlom; James W Hodge
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Cancer immunology, immunotherapy : CII 2007;56(12):1897-910.
2007: Mary Litzinger; Romaine Fernando; Tyler J Curiel; Douglas W Grosenbach; Jeffrey Schlom; Claudia Palena
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Blood 2007;110(9):3192-201.
2007: Philip M Arlen; Lisa Skarupa; Mary Pazdur; Mahesh Seetharam; Kwong-Yok Tsang; Douglas W Grosenbach; Jarett Feldman; Diane J Poole; Mary Litzinger; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Howard L Parnes; John Wright; William Dahut; Jeffrey Schlom; James L Gulley
Clinical safety of a viral vector based prostate cancer vaccine strategy.
The Journal of urology 2007;178(4 Pt 1):1515-20.
2007: Sven Mostböck; Silvia Vidal; Jeffrey Schlom; Helen Sabzevari
Enhanced levels of costimulation lead to reduced effector/memory CD8+ T cell functionality.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(6):3524-34.
2007: Mala Chakraborty; Jeffrey Schlom; James W Hodge
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
Cancer immunology, immunotherapy : CII 2007;56(9):1471-84.
2007: Junko Yokokawa; Tapan K Bera; Claudia Palena; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Ira Pastan; Jeffrey Schlom; Kwong-Yok Tsang
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
International journal of cancer. Journal international du cancer 2007;121(3):595-605.
2007: Jeffrey Schlom; Philip M Arlen; James L Gulley
Cancer vaccines: moving beyond current paradigms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3776-82.
2007: Marc R Theoret; Philip M Arlen; Mary Pazdur; William L Dahut; Jeffrey Schlom; James L Gulley
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Clinical genitourinary cancer 2007;5(5):347-50.
2007: Claudia Palena; Dmitry E Polev; Kwong-Yok Tsang; Romaine I Fernando; Mary Litzinger; Larisa L Krukovskaya; Ancha Baranova; Andrei P Kozlov; Jeffrey Schlom
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2471-8.
2007: Chie Kudo-Saito; Elizabeth K Wansley; M Eilene Gruys; Robert Wiltrout; Jeffrey Schlom; James W Hodge
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1936-46.
2007: Sven Mostböck; Marta Catalfamo; Yutaka Tagaya; Jeffrey Schlom; Helen Sabzevari
Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis.
Blood 2007;109(6):2488-95.
2007: David A Zaharoff; Connie J Rogers; Kenneth W Hance; Jeffrey Schlom; John W Greiner
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.
Vaccine 2007;25(11):2085-94.
2007: Deirdre O'Mahony; John C Morris; Cate Quinn; Wendy Gao; Wyndham H Wilson; Barry L Gause; Stefania Pittaluga; Sattva S Neelapu; Margaret Brown; Thomas A Fleisher; James L Gulley; Jeffrey Schlom; Robert B Nussenblatt; Paul Albert; Thomas A Davis; Israel Lowy; Mike Petrus; Thomas Waldmann; John Janik
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):958-64.
2007: Philip M Arlen; James L Gulley; Ravi A Madan; James W Hodge; Jeffrey Schlom
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Critical reviews in immunology 2007;27(5):451-62.
2007: Hadley J Sharp; Elizabeth K Wansley; Charlie T Garnett; Mala Chakraborty; Kevin A. Camphausen; Jeffrey Schlom; James W Hodge
Synergistic antitumor activity of immune strategies combined with radiation.
Frontiers in bioscience : a journal and virtual library 2007;12():4900-10.
2006: Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard Kaufman
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Vaccine 2006;24(23):4975-86.
2006: Eric Reits; James W Hodge; Carla A Herberts; Tom A M Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin A. Camphausen; Rosalie M Luiten; Arnoud de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A W Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques Neefjes
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
The Journal of experimental medicine 2006;203(5):1259-71.
2006: Paul C Chinn; Ron A Morena; Denise A Santoro; Timothy Kazules; Syed V S Kashmiri; Jeffrey Schlom; Nabil Hanna; Gary Braslawsky
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
Cancer biotherapy & radiopharmaceuticals 2006;21(2):106-16.
2006: Alexander Gelbard; Charlie T Garnett; Scott I Abrams; Vyomesh Patel; J Silvio Gutkind; Claudia Palena; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1897-905.
2006: Philip M Arlen; James L Gulley; Catherine Parker; Lisa Skarupa; Mary Pazdur; Dennis Panicali; Patricia Beetham; Kwong-Yok Tsang; Douglas W Grosenbach; Jarett Feldman; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Jeffrey Schlom; William Dahut
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1260-9.
2006: Howard Kaufman; Seth Cohen; Kenneth Cheung; Gail DeRaffele; Josephine Mitcham; Dorota Moroziewicz; Jeffrey Schlom; Charles Hesdorffer
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
Human gene therapy 2006;17(2):239-44.
2006: Claudia Palena; Scott I Abrams; Jeffrey Schlom; James W Hodge
Cancer vaccines: preclinical studies and novel strategies.
Advances in cancer research 2006;95():115-45.
2006: Charlie T Garnett; John W Greiner; Kwong-Yok Tsang; Chie Kudo-Saito; Douglas W Grosenbach; Mala Chakraborty; James L Gulley; Philip M Arlen; Jeffrey Schlom; James W Hodge
TRICOM vector based cancer vaccines.
Current pharmaceutical design 2006;12(3):351-61.
2006: James W Hodge; John W Greiner; Kwong-Yok Tsang; Helen Sabzevari; Chie Kudo-Saito; Douglas W Grosenbach; James L Gulley; Philip M Arlen; John L Marshall; Dennis Panicali; Jeffrey Schlom
Costimulatory molecules as adjuvants for immunotherapy.
Frontiers in bioscience : a journal and virtual library 2006;11():788-803.
2005: Claudia Palena; Kenneth A Foon; Dennis Panicali; Alicia Gómez Yafal; Jarasvech Chinsangaram; James W Hodge; Jeffrey Schlom; Kwong-Yok Tsang
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood 2005;106(10):3515-23.
2005: Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Vaccines with enhanced costimulation maintain high avidity memory CTL.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(6):3715-23.
2005: Junko Yokokawa; Claudia Palena; Philip M Arlen; Raffit Hassan; Mitchell Ho; Ira Pastan; Jeffrey Schlom; Kwong-Yok Tsang
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6342-51.
2005: Sixun Yang; Kwong-Yok Tsang; Jeffrey Schlom
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5603-15.
2005: Philip M Arlen; James L Gulley; Nushin Todd; Ronald Lieberman; Seth M Steinberg; Steve Morin; Anne Bastian; Jennifer Marte; Kwong-Yok Tsang; Patricia Beetham; Douglas W Grosenbach; Jeffrey Schlom; William Dahut
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
The Journal of urology 2005;174(2):539-46.
2005: Chie Kudo-Saito; Jeffrey Schlom; Kevin A. Camphausen; C Norman Coleman; James W Hodge
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4533-44.
2005: James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Multiple costimulatory modalities enhance CTL avidity.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(10):5994-6004.
2005: James L Gulley; Philip M Arlen; Anne Bastian; Steven Morin; Jennifer Marte; Patricia Beetham; Kwong-Yok Tsang; Junko Yokokawa; James W Hodge; Cynthia Ménard; Kevin A. Camphausen; C Norman Coleman; Francis Sullivan; Seth M Steinberg; Jeffrey Schlom; William Dahut
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3353-62.
2005: Syed V S Kashmiri; Roberto De Pascalis; Noreen R Gonzales; Jeffrey Schlom
SDR grafting--a new approach to antibody humanization.
Methods (San Diego, Calif.) 2005;36(1):25-34.
2005: Eva Reali; D Canter; Hasan Zeytin; Jeffrey Schlom; John W Greiner
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.
Vaccine 2005;23(22):2909-21.
2005: Michael A Morse; Timothy M Clay; Amy C Hobeika; Takuya Osada; Shubi Khan; Stephen Y (Steve) Chui; Donna Niedzwiecki; Dennis Panicali; Jeffrey Schlom; H Kim Lyerly
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):3017-24.
2005: Jun Zhou; Yutaka Tagaya; Roshanak Tolouei-Semnani; Jeffrey Schlom; Helen Sabzevari
Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs.
Blood 2005;105(8):3238-46.
2005: M E Christine Lutsiak; Roshanak Tolouei Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
Blood 2005;105(7):2862-8.
2005: Chie Kudo-Saito; Jeffrey Schlom; James W Hodge
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2416-26.
2005: Kwong-Yok Tsang; Claudia Palena; Junko Yokokawa; Philip M Arlen; James L Gulley; Gail P Mazzara; Linda Gritz; Alicia Gómez Yafal; Sandra Ogueta; Patricia Greenhalgh; Kelledy Manson; Dennis Panicali; Jeffrey Schlom
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1597-607.
2005: John L Marshall; James L Gulley; Philip M Arlen; Patricia Beetham; Kwong-Yok Tsang; Rebecca Slack; James W Hodge; Sandra Doren; Douglas W Grosenbach; Jimmy Hwang; Evelyn Fox; Lauretta Odogwu; Susie Park; Dennis Panicali; Jeffrey Schlom
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):720-31.
2005: Noreen R Gonzales; Roberto De Pascalis; Jeffrey Schlom; Syed V S Kashmiri
Minimizing the immunogenicity of antibodies for clinical application.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(1):31-43.
2004: Charlie T Garnett; Claudia Palena; Mala Chakraborty; Mala Chakarborty; Kwong-Yok Tsang; Jeffrey Schlom; James W Hodge
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
Cancer research 2004;64(21):7985-94.
2004: Dale C Slavin-Chiorini; Marta Catalfamo; Chie Kudo-Saito; James W Hodge; Jeffrey Schlom; Helen Sabzevari
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Cancer gene therapy 2004;11(10):665-80.
2004: Filippo Belardelli; Maria Ferrantini; Giorgio Parmiani; Jeffrey Schlom; Enrico Garaci
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
Cancer research 2004;64(18):6827-30.
2004: Noreen R Gonzales; Eduardo A Padlan; Roberto De Pascalis; Peter Schuck; Jeffrey Schlom; Syed V S Kashmiri
SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Molecular immunology 2004;41(9):863-72.
2004: Claudia Palena; MingZhu Zhu; Jeffrey Schlom; Kwong-Yok Tsang
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Blood 2004;104(1):192-9.
2004: Mala Chakraborty; Scott I Abrams; C Norman Coleman; Kevin A. Camphausen; Jeffrey Schlom; James W Hodge
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Cancer research 2004;64(12):4328-37.
2004: Howard Kaufman; Wei Wang; Judith Manola; Robert S DiPaola; Yoo-Joung Ko; Christopher Sweeney; Theresa L Whiteside; Jeffrey Schlom; George Wilding; Louis M Weiner
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2122-32.
2004: Hasan Zeytin; Arti C Patel; Connie J Rogers; Daniel Canter; Stephen D Hursting; Jeffrey Schlom; John W Greiner
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Cancer research 2004;64(10):3668-78.
2004: Diane E Milenic; Kayhan Garmestani; Ekaterina Dadachova; Lara L Chappell; Paul Albert; Donald Hill; Jeffrey Schlom; Martin W Brechbiel
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):135-47.
2004: Kwong-Yok Tsang; Claudia Palena; James L Gulley; Philip M Arlen; Jeffrey Schlom
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):2139-49.
2004: Chie Kudo-Saito; Jeffrey Schlom; James W Hodge
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):1090-9.
2004: Jeffrey Schlom; Claudia Palena; John W Greiner; Kwong-Yok Tsang; Douglas W Grosenbach; Helen Sabzevari; James L Gulley; Philip M Arlen; Erik S Kass; James W Hodge
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Developments in biologicals 2004;116():27-47.
2003: Claudia Palena; Philip M Arlen; Hasan Zeytin; John W Greiner; Jeffrey Schlom; Kwong-Yok Tsang
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine 2003;24(4):128-42.
2003: Roberto De Pascalis; Noreen R Gonzales; Eduardo A Padlan; Peter Schuck; Surinder Batra; Jeffrey Schlom; Syed V S Kashmiri
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5521-31.
2003: James W Hodge; Diane J Poole; Wilhelmina M Aarts; Alicia Gómez-Yafal; Linda Gritz; Jeffrey Schlom
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Cancer research 2003;63(22):7942-9.
2003: Andres Forero; Ruby F Meredith; Muhammad B Khazaeli; D Mark Carpenter; Sui Shen; Jennifer Thornton; Jeffrey Schlom; Albert F LoBuglio
A novel monoclonal antibody design for radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2003;18(5):751-9.
2003: Noreen R Gonzales; Eduardo A Padlan; Roberto De Pascalis; Peter Schuck; Jeffrey Schlom; Syed V S Kashmiri
Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Molecular immunology 2003;40(6):337-49.
2003: Philip M Arlen; James L Gulley; Kwong-Yok Tsang; Jeffrey Schlom
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Expert review of vaccines 2003;2(4):483-93.
2003: Philip M Arlen; James L Gulley; Claudia Palena; John Marshall; Jeffrey Schlom; Kwong-Yok Tsang
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
Journal of immunological methods 2003;279(1-2):183-92.
2003: Michael A Morse; Smita K Nair; Paul J Mosca; Amy C Hobeika; Timothy M Clay; Yuping Deng; David Boczkowski; Alan D Proia; Donna Neidzwiecki; Pierre-Alain Clavien; Herbert I Hurwitz; Jeffrey Schlom; Eli Gilboa; H Kim Lyerly
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
Cancer investigation 2003;21(3):341-9.
2003: Jeffrey Schlom; Helen Sabzevari; Douglas W Grosenbach; James W Hodge
A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Artificial cells, blood substitutes, and immobilization biotechnology 2003;31(2):193-228.
2003: James W Hodge; Douglas W Grosenbach; Wilhelmina M Aarts; Diane J Poole; Jeffrey Schlom
Vaccine therapy of established tumors in the absence of autoimmunity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1837-49.
2003: Claudia Palena; Jeffrey Schlom; Kwong-Yok Tsang
Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1616-27.
2003: Douglas W Grosenbach; Jeffrey Schlom; Linda Gritz; Alicia Gómez-Yafal; James W Hodge
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.
Cellular immunology 2003;222(1):45-57.
2003: SangKon Oh; James W Hodge; Jeffrey D Ahlers; Donald S. Burke; Jeffrey Schlom; Jay A Berzofsky
Selective induction of high avidity CTL by altering the balance of signals from APC.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(5):2523-30.
2003: James W Hodge; Kwong-Yok Tsang; Diane J Poole; Jeffrey Schlom
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S97-104; discussion S110-3.
2002: John W Greiner; Hasan Zeytin; Miriam R Anver; Jeffrey Schlom
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Cancer research 2002;62(23):6944-51.
2002: Zohreh Tatari-Calderone; Roshanak Tolouei Semnani; Thomas B Nutman; Jeffrey Schlom; Helen Sabzevari
Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(11):6162-9.
2002: Wilhelmina M Aarts; Jeffrey Schlom; James W Hodge
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Cancer research 2002;62(20):5770-7.
2002: Noreen R Gonzales; Peter Schuck; Jeffrey Schlom; Syed V S Kashmiri
Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies.
Journal of immunological methods 2002;268(2):197-210.
2002: James L Gulley; Alice P Chen; William Dahut; Philip M Arlen; Anne Bastian; Seth M Steinberg; Kwong Tsang; Dennis Panicali; Diane Poole; Jeffrey Schlom; J Michael Hamilton
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
The Prostate 2002;53(2):109-17.
2002: Roberto De Pascalis; Makoto Iwahashi; Midori Tamura; Eduardo A Padlan; Noreen R Gonzales; Ameurfina D Santos; Mariateresa Giuliano; Peter Schuck; Jeffrey Schlom; Syed V S Kashmiri
Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(6):3076-84.
2002: Ronald D Alvarez; Warner K Huh; Muhammad B Khazaeli; Ruby F Meredith; Edward E Partridge; Larry C Kilgore; William E Grizzle; Sui Shen; J Maxwell Austin; Mack N Barnes; Delicia Carey; Jeffrey Schlom; Albert F LoBuglio
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2806-11.
2002: John Schmitz; Eva Reali; James W Hodge; Arti Patel; Garland Davis; Jeffrey Schlom; John W Greiner
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Cancer research 2002;62(17):5058-64.
2002: Erik S Kass; John W Greiner; Judith A Kantor; Kwong-Yok Tsang; Fiorella Guadagni; Zhong Chen; Bradly Clark; Roberto De Pascalis; Jeffrey Schlom; Carter Van Waes
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer research 2002;62(17):5049-57.
2002: Diane E Milenic; Kayhan Garmestani; Lara L Chappell; Ekaterina Dadachova; Alexander T Yordanov; Dangshe Ma; Jeffrey Schlom; Martin W Brechbiel
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Nuclear medicine and biology 2002;29(4):431-42.
2002: Stephen J Kennel; Martin W Brechbiel; Diane E Milenic; Jeffrey Schlom; Saed Mirzadeh
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Cancer biotherapy & radiopharmaceuticals 2002;17(2):219-31.
2002: Michael A Morse; Smita K Nair; David Boczkowski; Douglas Tyler; Herbert I Hurwitz; Alan D Proia; Timothy M Clay; Jeffrey Schlom; Eli Gilboa; H Kim Lyerly
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
International journal of gastrointestinal cancer 2002;32(1):1-6.
2002: James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.
Cancer detection and prevention 2002;26(4):275-91.
2002: Hiroshi Terasawa; Kwong-Yok Tsang; James L Gulley; Philip M Arlen; Jeffrey Schlom
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):41-53.
2001: P Shankar; Jeffrey Schlom; James W Hodge
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Vaccine 2001;20(5-6):744-55.
2001: Kwong-Yok Tsang; MingZhu Zhu; J Even; James L Gulley; Philip M Arlen; Jeffrey Schlom
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer research 2001;61(20):7568-76.
2001: Ruby F Meredith; Ronald D Alvarez; Edward E Partridge; Muhammad B Khazaeli; C Y Lin; Daniel J Macey; J Maxwell Austin; Larry C Kilgore; William E Grizzle; Jeffrey Schlom; Albert F LoBuglio
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Cancer biotherapy & radiopharmaceuticals 2001;16(4):305-15.
2001: Eva Reali; John W Greiner; Angelo Corti; H J Gould; F Bottazzoli; G Paganelli; Jeffrey Schlom; Antonio G Siccardi
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
Cancer research 2001;61(14):5517-22.
2001: Ariel Rad; Jeffrey Schlom; James W Hodge
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Critical reviews in oncology/hematology 2001;39(1-2):43-57.
2001: Douglas W Grosenbach; J C Barrientos; Jeffrey Schlom; James W Hodge
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Cancer research 2001;61(11):4497-505.
2001: James W Hodge; Douglas W Grosenbach; Ariel Rad; Mariateresa Giuliano; Helen Sabzevari; Jeffrey Schlom
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Vaccine 2001;19(25-26):3552-67.
2001: MingZhu Zhu; H Terasawa; James L Gulley; Dennis Panicali; Philip M Arlen; Jeffrey Schlom; Kwong-Yok Tsang
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Cancer research 2001;61(9):3725-34.
2001: Diane E Milenic; M Roselli; Saed Mirzadeh; CG Pippin; Otto A Gansow; David Colcher; Martin W Brechbiel; Jeffrey Schlom
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Cancer biotherapy & radiopharmaceuticals 2001;16(2):133-46.
2001: Syed V S Kashmiri; Makoto Iwahashi; M Tamura; Eduardo A Padlan; Diane E Milenic; Jeffrey Schlom
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Critical reviews in oncology/hematology 2001;38(1):3-16.
2001: Fiorella Guadagni; Judith A Kantor; Simona Aloe; MD Carone; Antonella Spila; Roberta D'Alessandro; MR Abbolito; Maurizio Cosimelli; Franco Graziano; Fabio Carboni; S Carlini; Pasquale Perri; F Sciarretta; John W Greiner; Syed V S Kashmiri; Seth M Steinberg; Mario Roselli; Jeffrey Schlom
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Cancer research 2001;61(6):2523-32.
2001: Richard M Simon; Seth M Steinberg; M Hamilton; A Hildesheim; Samir N Khleif; L W Kwak; CRYSTAL MACKALL; Jeffrey Schlom; Suzanne Topalian; Jay A Berzofsky
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1848-54.
2001: Helen Sabzevari; J Kantor; A Jaigirdar; Yutaka Tagaya; M Naramura; J Hodge; J Bernon; Jeffrey Schlom
Acquisition of CD80 (B7-1) by T cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(4):2505-13.
2001: Erik S Kass; Dennis Panicali; Gail P Mazzara; Jeffrey Schlom; John W Greiner
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Cancer research 2001;61(1):206-14.
2000: Philip M Arlen; Kwong-Yok Tsang; John L Marshall; A Chen; Seth M Steinberg; D Poole; PH Hand; Jeffrey Schlom; J Michael Hamilton
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Cancer immunology, immunotherapy : CII 2000;49(10):517-29.
2000: John L Marshall; RJ Hoyer; M A Toomey; K Faraguna; P Chang; E Richmond; J E Pedicano; Edmund Gehan; R A Peck; Philip M Arlen; Kwong-Yok Tsang; Jeffrey Schlom
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3964-73.
2000: James W Hodge; Ariel Rad; Douglas W Grosenbach; Helen Sabzevari; Alicia Gómez Yafal; Linda Gritz; Jeffrey Schlom
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Journal of the National Cancer Institute 2000;92(15):1228-39.
2000: SD Patel; Marina Moskalenko; T Tian; D Smith; R McGuinness; L Chen; G A Winslow; Syed V S Kashmiri; Jeffrey Schlom; C P Stanners; Mitchell Finer; James G McArthur
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
Cancer gene therapy 2000;7(8):1127-34.
2000: Erik S Kass; J Parker; Jeffrey Schlom; John W Greiner
Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.
Cytokine 2000;12(7):960-71.
2000: Joseph P Eder; Philip W Kantoff; K Roper; G X Xu; G J Bubley; J Boyden; Linda Gritz; Gail P Mazzara; William K Oh; Philip M Arlen; Kwong-Yok Tsang; Dennis Panicali; Jeffrey Schlom; Donald Kufe
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1632-8.
2000: E Salazar; S Zaremba; Philip M Arlen; Kwong-Yok Tsang; Jeffrey Schlom
Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
International journal of cancer. Journal international du cancer 2000;85(6):829-38.
2000: Yvonne R Freund; Jon C Mirsalis; D G Fairchild; J Brune; L A Hokama; Janice Schindler-Horvat; Joseph E Tomaszewski; James W Hodge; Jeffrey Schlom; Judith A Kantor; Charles A Tyson; Susan J Donohue
Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.
International journal of cancer. Journal international du cancer 2000;85(4):508-17.
2000: M Tamura; Diane E Milenic; Makoto Iwahashi; Eduardo A Padlan; Jeffrey Schlom; Syed V S Kashmiri
Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(3):1432-41.
2000: James W Hodge; Jeffrey Schlom
Costimulatory molecules in vaccine design.
Ernst Schering Research Foundation workshop 2000;(30):23-52.
2000: M Z Zhu; J Marshall; D Cole; Jeffrey Schlom; Kwong-Yok Tsang
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):24-33.
1999: Jeffrey Schlom; Kwong-Yok Tsang; Judith A Kantor; Scott I Abrams; S Zaremba; J Greiner; James W Hodge
Strategies in the development of recombinant vaccines for colon cancer.
Seminars in oncology 1999;26(6):672-82.
1999: James W Hodge; Helen Sabzevari; Alicia Gómez Yafal; Linda Gritz; MG Lorenz; Jeffrey Schlom
A triad of costimulatory molecules synergize to amplify T-cell activation.
Cancer research 1999;59(22):5800-7.
1999: James W Hodge; Jeffrey Schlom
Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
Cancer research 1999;59(20):5106-11.
1999: Makoto Iwahashi; Diane E Milenic; Eduardo A Padlan; Roberto Bei; Jeffrey Schlom; Syed V S Kashmiri
CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Molecular immunology 1999;36(15-16):1079-91.
1999: Ruby F Meredith; Muhammad B Khazaeli; Daniel J Macey; William E Grizzle; M Mayo; Jeffrey Schlom; Charles D Russell; Albert F LoBuglio
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3254s-3258s.
1999: Ameurfina D Santos; Syed V S Kashmiri; PH Hand; Jeffrey Schlom; Eduardo A Padlan
Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3118s-3123s.
1999: Robert M Conry; Muhammad B Khazaeli; Mansoor N Saleh; Karen O Allen; Daunte L Barlow; Susan E Moore; D Craig; Ramin B Arani; Jeffrey Schlom; Albert F LoBuglio
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2330-7.
1999: M Roselli; Diane E Milenic; Martin W Brechbiel; Saed Mirzadeh; CG Pippin; Otto A Gansow; David Colcher; Jeffrey Schlom
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
Cancer biotherapy & radiopharmaceuticals 1999;14(3):209-20.
1999: Michael A Morse; Y Deng; Doris Coleman; S Hull; E Kitrell-Fisher; Smita Nair; Jeffrey Schlom; M E Ryback; H Kim Lyerly
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1331-8.
1999: JA Bristol; Jeffrey Schlom; Scott I Abrams
Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Cellular immunology 1999;194(1):78-89.
1999: M L Cutler; W Lesley Shupert; Jeffrey Schlom; Judith A Kantor
Low-level transforming activity of an activated Ras gene under the control of a vaccinia virus p40 promoter is abrogated by truncation of the Ras cDNA.
Vaccine 1999;17(18):2275-83.
1999: MG Lorenz; Judith A Kantor; Jeffrey Schlom; James W Hodge
Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
Human gene therapy 1999;10(7):1095-103.
1999: MG Lorenz; Judith A Kantor; Jeffrey Schlom; James W Hodge
Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus.
Human gene therapy 1999;10(4):623-31.
1999: Samir N Khleif; Scott I Abrams; J Michael Hamilton; Elke Bergmann-Leitner; A Chen; A Bastian; S Bernstein; Y Chung; Carmen J Allegra; Jeffrey Schlom
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):155-65.
1999: R M Kalus; Judith A Kantor; Linda Gritz; Alicia Gómez-Yafal; Gail P Mazzara; Jeffrey Schlom; James W Hodge
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.
Vaccine 1999;17(7-8):893-903.
1999: Erik S Kass; Jeffrey Schlom; J Thompson; Fiorella Guadagni; Paolo Graziano; John W Greiner
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Cancer research 1999;59(3):676-83.
1999: R P McGuinness; Ying Ge; SD Patel; Syed V S Kashmiri; H S Lee; PH Hand; Jeffrey Schlom; Mitchell Finer; James G McArthur
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.
Human gene therapy 1999;10(2):165-73.
1999: John L Marshall; Michael J Hawkins; Kwong-Yok Tsang; E Richmond; J E Pedicano; M Z Zhu; Jeffrey Schlom
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):332-7.
1999: H S Lee; L Shu; Roberto De Pascalis; Mariateresa Giuliano; M Zhu; Eduardo A Padlan; PH Hand; Jeffrey Schlom; Hyo Jeong Hong; Syed V S Kashmiri
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions.
Molecular immunology 1999;36(1):61-71.
1998: K Vogel; Judith A Kantor; L Wood; R Rivera; Jeffrey Schlom
Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses.
Cellular immunology 1998;190(1):61-7.
1998: Pierpaolo Correale; K Walmsley; S Zaremba; MingZhu Zhu; Jeffrey Schlom; Kwong-Yok Tsang
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):3186-94.
1998: Jeffrey Schlom; Kwong-Yok Tsang; Judith A Kantor; Scott I Abrams; S Zaremba; J Greiner; James W Hodge
Cancer vaccine development.
Expert opinion on investigational drugs 1998;7(9):1439-52.
1998: Elke Bergmann-Leitner; Judith A Kantor; W Lesley Shupert; Jeffrey Schlom; Scott I Abrams
Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Cellular immunology 1998;187(2):103-16.
1998: Roberto Bei; V Guptill; Laura Masuelli; Syed V S Kashmiri; Raffaella Muraro; Luigi Frati; Jeffrey Schlom; Judith A Kantor
The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(3):159-69.
1998: Diane E Milenic; M Roselli; Martin W Brechbiel; CG Pippin; T J McMurray; Jorge Carrasquillo; David Colcher; R Lambrecht; Otto A Gansow; Jeffrey Schlom
In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand.
European journal of nuclear medicine 1998;25(5):471-80.
1998: JA Bristol; Jeffrey Schlom; Scott I Abrams
Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(5):2433-41.
1997: Scott I Abrams; Samir N Khleif; Elke Bergmann-Leitner; Judith A Kantor; Y Chung; J Michael Hamilton; Jeffrey Schlom
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Cellular immunology 1997;182(2):137-51.
1997: Kwong-Yok Tsang; MingZhu Zhu; C A Nieroda; Pierpaolo Correale; S Zaremba; J Michael Hamilton; D Cole; C Lam; Jeffrey Schlom
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2439-49.
1997: JP McLaughlin; Scott Abrams; Judith A Kantor; M J Dobrzanski; J Greenbaum; Jeffrey Schlom; John W Greiner
Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(6):449-59.
1997: S Zaremba; E Barzaga; MingZhu Zhu; N Soares; Kwong-Yok Tsang; Jeffrey Schlom
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Cancer research 1997;57(20):4570-7.
1997: D C Slavin-Chiorini; Syed V S Kashmiri; H S Lee; Diane E Milenic; Diane J Poole; E Bernon; Jeffrey Schlom; PH Hand
A CDR-grafted (humanized) domain-deleted antitumor antibody.
Cancer biotherapy & radiopharmaceuticals 1997;12(5):305-16.
1997: Fiorella Guadagni; Mario Roselli; Maurizio Cosimelli; Antonella Spila; Francesco Cavaliere; R Arcuri; Roberta D'Alessandro; PL Fracasso; Vincenzo Casale; A Vecchione; Carlo U Casciani; John W Greiner; Jeffrey Schlom
Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.
International journal of cancer. Journal international du cancer 1997;72(6):949-54.
1997: G L Prasad; H S Lee; Makoto Iwahashi; Diane E Milenic; Scott Abrams; Jeffrey Schlom; Syed V S Kashmiri
In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response.
Cancer gene therapy 1997;4(4):253-9.
1997: K Uzendoski; Judith A Kantor; Scott I Abrams; Jeffrey Schlom; James W Hodge
Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses.
Human gene therapy 1997;8(7):851-60.
1997: T Liu; Ruby F Meredith; Mansoor N Saleh; Richard H Wheeler; Muhammad B Khazaeli; W E Plott; Jeffrey Schlom; Albert F LoBuglio
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Cancer biotherapy & radiopharmaceuticals 1997;12(2):79-87.
1997: James W Hodge; JP McLaughlin; Judith A Kantor; Jeffrey Schlom
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Vaccine 1997;15(6-7):759-68.
1997: Ronald D Alvarez; Edward E Partridge; Muhammad B Khazaeli; G Plott; M Austin; Larry C Kilgore; Charles D Russell; T Liu; William E Grizzle; Jeffrey Schlom; Albert F LoBuglio; Ruby F Meredith
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Gynecologic oncology 1997;65(1):94-101.
1997: Pierpaolo Correale; K Walmsley; C Nieroda; S Zaremba; MingZhu Zhu; Jeffrey Schlom; Kwong-Yok Tsang
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Journal of the National Cancer Institute 1997;89(4):293-300.
1997: Scott I Abrams; James W Hodge; JP McLaughlin; Seth M Steinberg; Judith A Kantor; Jeffrey Schlom
Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):48-59.
1997: Junji Akagi; James W Hodge; JP McLaughlin; Linda Gritz; Gail P Mazzara; Donald Kufe; Jeffrey Schlom; Judith A Kantor
Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):38-47.
1996: M E Schott; D T Wells; Jeffrey Schlom; Scott I Abrams
Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Cellular immunology 1996;174(2):199-209.
1996: Ruby F Meredith; Muhammad B Khazaeli; W E Plott; William E Grizzle; T Liu; Jeffrey Schlom; Charles D Russell; Richard H Wheeler; Albert F LoBuglio
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1811-8.
1996: Ruby F Meredith; Edward E Partridge; Ronald D Alvarez; Muhammad B Khazaeli; G Plott; Charles D Russell; Richard H Wheeler; T Liu; William E Grizzle; Jeffrey Schlom; Albert F LoBuglio
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(9):1491-6.
1996: B Yu; Jorge Carrasquillo; Diane E Milenic; Y Chung; P Perentesis; I Feuerestein; D Eggensperger; C F Qi; Chang H Paik; J Reynolds; Jean L Grem; G Curt; K Siler; Jeffrey Schlom; Carmen J Allegra
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1798-809.
1996: JP McLaughlin; Jeffrey Schlom; Judith A Kantor; John W Greiner
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
Cancer research 1996;56(10):2361-7.
1996: Scott I Abrams; S F Stanziale; S D Lunin; S Zaremba; Jeffrey Schlom
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
European journal of immunology 1996;26(2):435-43.
1996: Scott I Abrams; P H Hand; Kwong-Yok Tsang; Jeffrey Schlom
Mutant ras epitopes as targets for cancer vaccines.
Seminars in oncology 1996;23(1):118-34.
1996: Jeffrey Schlom; Judith A Kantor; Scott Abrams; K Y Tsang; D Panicali; J M Hamilton
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.
Breast cancer research and treatment 1996;38(1):27-39.
1995: T Mulligan; Jorge Carrasquillo; Y Chung; Diane E Milenic; Jeffrey Schlom; I Feuerstein; Chang H Paik; P Perentesis; J Reynolds; G Curt
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1447-54.
1995: L Shu; C F Qi; PH Hand; Jeffrey Schlom; Syed V S Kashmiri
Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein.
Immunotechnology : an international journal of immunological engineering 1995;1(3-4):231-41.
1995: D C Slavin-Chiorini; Syed V S Kashmiri; Jeffrey Schlom; Benjamin F Calvo; L M Shu; M E Schott; Diane E Milenic; P Snoy; Jorge Carrasquillo; K Anderson
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
Cancer research 1995;55(23 Suppl):5957s-5967s.
1995: Roberto Bei; Jeffrey Schlom; Syed V S Kashmiri
Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein.
Journal of immunological methods 1995;186(2):245-55.
1995: James W Hodge; Jeffrey Schlom; S J Donohue; J E Tomaszewski; C W Wheeler; B S Levine; Linda Gritz; D Panicali; Judith A Kantor
A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.
International journal of cancer. Journal international du cancer 1995;63(2):231-7.
1995: Syed V S Kashmiri; L Shu; E A Padlan; Diane E Milenic; Jeffrey Schlom; PH Hand
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Hybridoma 1995;14(5):461-73.
1995: Mansoor N Saleh; Muhammad B Khazaeli; Richard H Wheeler; R P Bucy; T Liu; MP Everson; David H Munn; Jeffrey Schlom; Albert F LoBuglio
Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
Cancer research 1995;55(19):4339-46.
1995: Scott I Abrams; M J Dobrzanski; D T Wells; S F Stanziale; S Zaremba; Laura Masuelli; Judith A Kantor; Jeffrey Schlom; L ] Masuelle L [corrected to Masuelli
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
European journal of immunology 1995;25(9):2588-97.
1995: James W Hodge; JP McLaughlin; Scott I Abrams; W Lesley Shupert; Jeffrey Schlom; Judith A Kantor
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Cancer research 1995;55(16):3598-603.
1995: Kwong-Yok Tsang; S Zaremba; CA Nieroda; M Z Zhu; J Michael Hamilton; Jeffrey Schlom
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
Journal of the National Cancer Institute 1995;87(13):982-90.
1995: C F Qi; CA Nieroda; R De Filippi; John W Greiner; Pierpaolo Correale; Jeffrey Schlom; Kwong-Yok Tsang
Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Immunology letters 1995;47(1-2):15-24.
1995: J F Karr; Judith A Kantor; PH Hand; D L Eggensperger; Jeffrey Schlom
The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Cancer research 1995;55(11):2455-62.
1995: Mario Roselli; C L Hitchcock; A Molinolo; Diane E Milenic; David Colcher; E W Martin; George Hinkle; Jeffrey Schlom
Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Anticancer research 1995;15(3):975-84.
1995: C Dansky-Ullmann; Michael L Salgaller; S Adams; Jeffrey Schlom; John W Greiner
Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta.
Cytokine 1995;7(2):118-29.
1995: Roberto Bei; C Paranavitana; Diane E Milenic; Syed V S Kashmiri; Jeffrey Schlom
Generation, purification, and characterization of a recombinant source of human prostate-specific antigen.
Journal of clinical laboratory analysis 1995;9(4):261-8.
1994: Roberto Bei; Judith A Kantor; Syed V S Kashmiri; Scott Abrams; Jeffrey Schlom
Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(4):275-82.
1994: H Yamaue; Syed V S Kashmiri; R De Filippi; CA Nieroda; J R Yannelli; Kwong-Yok Tsang; Jeffrey Schlom
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(4):262-74.
1994: J R Sawyer; Jeffrey Schlom; Syed V S Kashmiri
The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli.
Protein engineering 1994;7(11):1401-6.
1994: James W Hodge; Scott Abrams; Jeffrey Schlom; Judith A Kantor
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Cancer research 1994;54(21):5552-5.
1994: S Shimada; M Ogawa; M Takahashi; Jeffrey Schlom; John W Greiner
Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon.
Cancer research 1994;54(14):3831-6.
1994: Roberto Bei; Judith A Kantor; Syed V S Kashmiri; Jeffrey Schlom
Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen.
Molecular immunology 1994;31(10):771-80.
1994: Ruby F Meredith; Anton J Bueschen; Muhammad B Khazaeli; W E Plott; William E Grizzle; Richard H Wheeler; Jeffrey Schlom; Charles D Russell; T Liu; Albert F LoBuglio
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(6):1017-22.
1994: FJ Primus; M D Finch; S A Wetzel; A M Masci; Jeffrey Schlom; Syed V S Kashmiri
Monoclonal antibody gene transfer. Implications for tumor-specific cell-mediated cytotoxicity.
Annals of the New York Academy of Sciences 1994;716():154-65; discussion 165-6.
1994: Robert M Conry; Albert F LoBuglio; Judith A Kantor; Jeffrey Schlom; F Loechel; Susan E Moore; L A Sumerel; Daunte L Barlow; Scott Abrams; David T Curiel
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
Cancer research 1994;54(5):1164-8.
1994: John W Greiner; Fiorella Guadagni; Mario Roselli; C D Ullmann; CA Nieroda; Jeffrey Schlom
Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
Diseases of the colon and rectum 1994;37(2 Suppl):S100-5.
1994: M E Schott; Jeffrey Schlom; K Siler; Diane E Milenic; D Eggensperger; David Colcher; R Cheng; W J Kruper; W Fordyce; W Goeckeler
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
Cancer 1994;73(3 Suppl):993-8.
1994: PH Hand; Syed V S Kashmiri; Jeffrey Schlom
Potential for recombinant immunoglobulin constructs in the management of carcinoma.
Cancer 1994;73(3 Suppl):1105-13.
1993: Chantal Abergel; E A Padlan; Syed V S Kashmiri; Diane E Milenic; Benjamin F Calvo; Jeffrey Schlom
Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.
Proteins 1993;17(4):438-43.
1993: Mansoor N Saleh; Muhammad B Khazaeli; William E Grizzle; Richard H Wheeler; S Lawson; T Liu; C Russel; Ruby F Meredith; Jeffrey Schlom; Albert F LoBuglio
A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Cancer research 1993;53(19):4555-62.
1993: Ruby F Meredith; Muhammad B Khazaeli; William E Grizzle; R A Orr; G Plott; M M Urist; T Liu; Charles D Russell; Richard H Wheeler; Jeffrey Schlom
Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Human antibodies and hybridomas 1993;4(4):190-7.
1993: L Shu; C F Qi; Jeffrey Schlom; Syed V S Kashmiri
Secretion of a single-gene-encoded immunoglobulin from myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(17):7995-9.
1993: T Yokota; Diane E Milenic; M Whitlow; J F Wood; S L Hubert; Jeffrey Schlom
Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Cancer research 1993;53(16):3776-83.
1993: Judith A Kantor; Scott Abrams; Kari R Irvine; P Snoy; H Kaufman; Jeffrey Schlom
Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen.
Annals of the New York Academy of Sciences 1993;690():370-3.
1993: FJ Primus; M D Finch; A M Masci; Jeffrey Schlom; Syed V S Kashmiri
Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes.
Cancer research 1993;53(14):3355-61.
1993: Michael L Salgaller; Roberto Bei; Jeffrey Schlom; D J Poole; Paul F Robbins
Baculovirus recombinants expressing the human carcinoembryonic antigen gene.
Cancer research 1993;53(9):2154-61.
1993: Kwong-Yok Tsang; Syed V S Kashmiri; C F Qi; CA Nieroda; Benjamin F Calvo; R De Filippi; John W Greiner; FJ Primus; Jeffrey Schlom
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.
Immunology letters 1993;36(2):179-85.
1993: Kari R Irvine; Jeffrey Schlom
Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.
Cancer immunology, immunotherapy : CII 1993;36(5):281-92.
1993: Kwong-Yok Tsang; Syed V S Kashmiri; R De Filippi; C F Qi; Benjamin F Calvo; L Shu; CA Nieroda; John W Greiner; Jeffrey Schlom
A human T cell line engineered to secrete chimeric monoclonal antibody.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):143-52.
1993: Paul F Robbins; D Eggensperger; C F Qi; Jeffrey Schlom
Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas.
International journal of cancer. Journal international du cancer 1993;53(6):892-7.
1993: John W Greiner; C D Ullmann; CA Nieroda; C F Qi; D Eggensperger; S Shimada; Seth M Steinberg; Jeffrey Schlom
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
Cancer research 1993;53(3):600-8.
1993: D C Slavin-Chiorini; P H Horan Hand; Syed V S Kashmiri; Benjamin F Calvo; S Zaremba; Jeffrey Schlom
Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.
International journal of cancer. Journal international du cancer 1993;53(1):97-103.
1993: PH Hand; Paul F Robbins; Michael L Salgaller; D J Poole; Jeffrey Schlom
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies.
Cancer immunology, immunotherapy : CII 1993;36(2):65-75.
1993: K Siler; D Eggensperger; PH Hand; Diane E Milenic; L S Miller; D P Houchens; George Hinkle; Jeffrey Schlom
Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
Biotechnology therapeutics 1993;4(3-4):163-81.
1993: Benjamin F Calvo; Syed V S Kashmiri; P Hutzell; PH Hand; D C Slavin-Chiorini; Jeffrey Schlom; S Zaremba
Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody.
Cancer biotherapy 1993;8(1):95-109.
1992: Judith A Kantor; Kari R Irvine; Scott Abrams; P Snoy; R Olsen; J Greiner; H Kaufman; D Eggensperger; Jeffrey Schlom
Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Cancer research 1992;52(24):6917-25.
1992: M E Schott; Diane E Milenic; T Yokota; M Whitlow; J F Wood; W A Fordyce; R C Cheng; Jeffrey Schlom
Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.
Cancer research 1992;52(22):6413-7.
1992: C D Ullmann; Jeffrey Schlom; John W Greiner
Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):231-41.
1992: Ruby F Meredith; Muhammad B Khazaeli; T Liu; G Plott; Richard H Wheeler; C Russell; David Colcher; Jeffrey Schlom; D Shochat; Albert F LoBuglio
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(9):1648-53.
1992: Judith A Kantor; Kari R Irvine; Scott Abrams; H Kaufman; J DiPietro; Jeffrey Schlom
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Journal of the National Cancer Institute 1992;84(14):1084-91.
1992: T Yokota; Diane E Milenic; M Whitlow; Jeffrey Schlom
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Cancer research 1992;52(12):3402-8.
1992: John W Greiner; Fiorella Guadagni; D Goldstein; R V Smalley; Ernest C Borden; J F Simpson; A Molinolo; Jeffrey Schlom
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):735-46.
1992: Jeffrey Schlom; D Eggensperger; David Colcher; A Molinolo; D Houchens; L S Miller; George Hinkle; K Siler
Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.
Cancer research 1992;52(5):1067-72.
1992: Ruby F Meredith; Muhammad B Khazaeli; W E Plott; Mansoor N Saleh; T Liu; L F Allen; Charles D Russell; R A Orr; David Colcher; Jeffrey Schlom
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(1):23-9.
1992: PH Hand; Benjamin F Calvo; Diane E Milenic; T Yokota; M Finch; P Snoy; Kayhan Garmestani; Otto A Gansow; Jeffrey Schlom; Syed V S Kashmiri
Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
Cancer immunology, immunotherapy : CII 1992;35(3):165-74.
1992: David Colcher; Diane E Milenic; Jeffrey Schlom
Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.
Targeted diagnosis and therapy 1992;6():23-44.
1992: P Horan Hand; J F Simpson; M Kuroki; R Parker; Jeffrey Schlom
Reactivities of an anti-CEA peptide monoclonal antibody.
The International journal of biological markers 1992;7(1):1-15.
1991: Diane E Milenic; T Yokota; D R Filpula; Malcolm Finkelman; S W Dodd; J F Wood; M Whitlow; P Snoy; Jeffrey Schlom
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Cancer research 1991;51(23 Pt 1):6363-71.
1991: S Shimada; M Ogawa; Jeffrey Schlom; John W Greiner
Identification of a novel tumor-associated Mr 110,000 gene product in human gastric carcinoma cells that is immunologically related to carcinoembryonic antigen.
Cancer research 1991;51(20):5694-703.
1991: John W Greiner; Fiorella Guadagni; D Goldstein; Ernest C Borden; R E Ritts; P Witt; A F LoBuglio; M N Saleh; Jeffrey Schlom
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.
Cancer research 1991;51(16):4155-63.
1991: H Kaufman; Jeffrey Schlom; Judith A Kantor
A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA).
International journal of cancer. Journal international du cancer 1991;48(6):900-7.
1991: Paul F Robbins; Judith A Kantor; Michael L Salgaller; PH Hand; P D Fernsten; Jeffrey Schlom
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line.
Cancer research 1991;51(14):3657-62.
1991: Jeffrey Schlom; K Siler; Diane E Milenic; D Eggensperger; David Colcher; L S Miller; D Houchens; R Cheng; D Kaplan; W Goeckeler
Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
Cancer research 1991;51(11):2889-96.
1991: Fiorella Guadagni; Giampaolo Tortora; Mario Roselli; Timothy Clair; Yoon S Cho-Chung; Jeffrey Schlom; John W Greiner
Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic AMP analogue: a comparison with interferon-gamma.
International journal of cancer. Journal international du cancer 1991;48(3):413-22.
1991: J F Simpson; F J Primus; Jeffrey Schlom
Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas.
The International journal of biological markers 1991;6(2):83-90.
1991: T K Pendurthi; Jeffrey Schlom; FJ Primus
Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(1):2-12.
1991: P D Fernsten; FJ Primus; John W Greiner; J F Simpson; Jeffrey Schlom
Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
Cancer research 1991;51(3):926-34.
1991: Fiorella Guadagni; Mario Roselli; Jeffrey Schlom; John W Greiner
Regulation of human tumor antigen expression by biological response modifiers (BRMs).
Annali dell'Istituto superiore di sanità 1991;27(1):71-8.
1991: John W Greiner; R V Smalley; Ernest C Borden; E W Martin; Fiorella Guadagni; Mario Roselli; Jeffrey Schlom
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.
Journal of surgical oncology. Supplement 1991;2():9-13.
1991: Fiorella Guadagni; Jeffrey Schlom; John W Greiner
In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):409-12.
1991: Jeffrey Schlom; Diane E Milenic; Mario Roselli; David Colcher; R Bird; Syd Johnson; K D Hardman; Fiorella Guadagni; John W Greiner
New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):425-35.
1991: David Colcher; Diane E Milenic; P Ferroni; Mario Roselli; Jeffrey Schlom
In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):395-401.
1991: Mario Roselli; Jeffrey Schlom; Otto A Gansow; Martin W Brechbiel; Saed Mirzadeh; CG Pippin; Diane E Milenic; David Colcher
Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):389-94.
1991: P Ferroni; Diane E Milenic; Mario Roselli; Jorge Carrasquillo; A Raubitschek; Jeffrey Schlom; David Colcher
Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):383-7.
1991: Kwong-Yok Tsang; M D Finch; FJ Primus; Jeffrey Schlom
Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII 1991;34(1):9-16.
1990: T K Pendurthi; R Parker; Jeffrey Schlom; FJ Primus
Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
International journal of cancer. Journal international du cancer 1990;46(6):1021-8.
1990: Fiorella Guadagni; P L Witt; Paul F Robbins; Jeffrey Schlom; John W Greiner
Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.
Cancer research 1990;50(19):6248-55.
1990: P Ferroni; Diane E Milenic; Mario Roselli; Jorge Carrasquillo; A Raubitschek; Jeffrey Schlom; David Colcher
Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols.
The International journal of biological markers 1990;5(4):166-76.
1990: R S Katari; P D Fernsten; Jeffrey Schlom
Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas.
Cancer research 1990;50(16):4885-90.
1990: M Kuroki; P D Fernsten; D Wunderlich; David Colcher; J F Simpson; D J Poole; Jeffrey Schlom
Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies.
Cancer research 1990;50(16):4872-9.
1990: David Colcher; R Bird; Mario Roselli; K D Hardman; Syd Johnson; S Pope; S W Dodd; M W Pantoliano; Diane E Milenic; Jeffrey Schlom
In vivo tumor targeting of a recombinant single-chain antigen-binding protein.
Journal of the National Cancer Institute 1990;82(14):1191-7.
1990: David Colcher; Diane E Milenic; P Ferroni; Jorge Carrasquillo; James C Reynolds; Mario Roselli; Steven M Larson; Jeffrey Schlom
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(7):1133-42.
1990: Jeffrey Schlom; A Molinolo; J F Simpson; K Siler; Mario Roselli; George Hinkle; D P Houchens; David Colcher
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
Journal of the National Cancer Institute 1990;82(9):763-71.
1990: A Molinolo; J F Simpson; A Thor; Jeffrey Schlom
Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
Cancer research 1990;50(4):1291-8.
1990: Jeffrey Schlom; PH Hand; John W Greiner; David Colcher; S Shrivastav; Jorge Carrasquillo; James C Reynolds; Steven M Larson; A Raubitschek
Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.
Cancer research 1990;50(3 Suppl):820s-827s.
1990: FJ Primus; T K Pendurthi; P Hutzell; Syed V S Kashmiri; D C Slavin; Robert Callahan; Jeffrey Schlom
Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1990;31(6):349-57.
1990: P Ferroni; Diane E Milenic; Jeffrey Schlom; David Colcher
Assay for the detection of anti-idiotypic antibodies to monoclonal antibody B72.3.
Journal of clinical laboratory analysis 1990;4(6):465-73.
1990: Jeffrey Schlom; K Siler; David Colcher; Jorge Carrasquillo; James C Reynolds; P Sugarbaker; Steven M Larson
Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview.
Acta radiologica. Supplementum 1990;374():123-8.
1989: M Kuroki; John W Greiner; J F Simpson; FJ Primus; Fiorella Guadagni; Jeffrey Schlom
Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies.
International journal of cancer. Journal international du cancer 1989;44(2):208-18.
1989: Judith A Kantor; R Tran; J Greiner; S Pestka; P B Fisher; J E Shively; Jeffrey Schlom
Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon.
Cancer research 1989;49(10):2651-5.
1989: Mario Roselli; Jeffrey Schlom; Otto A Gansow; A Raubitschek; Saed Mirzadeh; Martin W Brechbiel; David Colcher
Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1989;30(5):672-82.
1989: Raffaella Muraro; M Nuti; P G Natali; A Bigotti; J F Simpson; FJ Primus; David Colcher; John W Greiner; Jeffrey Schlom
A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro-intestinal epithelium.
International journal of cancer. Journal international du cancer 1989;43(4):598-607.
1989: Fiorella Guadagni; Jeffrey Schlom; W W Johnston; C A Szpak; D Goldstein; Richard E Smalley; J F Simpson; Ernest C Borden; S Pestka; John W Greiner
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
Journal of the National Cancer Institute 1989;81(7):502-12.
1989: David Colcher; Diane E Milenic; Mario Roselli; A Raubitschek; G Yarranton; D King; J Adair; N Whittle; M Bodmer; Jeffrey Schlom
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Cancer research 1989;49(7):1738-45.
1989: S Shrivastav; Jeffrey Schlom; A Raubitschek; A Molinolo; J Simpson; PH Hand
Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts.
International journal of radiation oncology, biology, physics 1989;16(3):721-9.
1989: Renato Mariani-Costantini; Charles Theillet; P Hutzell; GR Merlo; Jeffrey Schlom; Robert Callahan
In situ detection of c-myc mRNA in adenocarcinomas, adenomas, and mucosa of human colon.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1989;37(3):293-8.
1989: Jeffrey Schlom; David Colcher; C A Szpak; W W Johnston; P Sugarbaker; Jorge Carrasquillo; James C Reynolds; Steven M Larson
A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors.
Progress in clinical and biological research 1989;288():63-72.
1989: Steven M Larson; A Raubitschek; James C Reynolds; Ronald D Neumann; K E Hellstrom; I Hellstrom; David Colcher; Jeffrey Schlom; E Glatstein; Jorge Carrasquillo
Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(2):153-8.
1989: Jeffrey Schlom; David Colcher; Mario Roselli; Jorge Carrasquillo; James C Reynolds; Steven M Larson; P Sugarbaker; S E Tuttle; E W Martin
Tumor targeting with monoclonal antibody B72.3.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(2):137-42.
1989: Robert Callahan; M O Weeks; N Ohuchi; Jeffrey Schlom
Retroviral-related genes, proto-oncogenes, and breast cancer.
Immunology series 1989;43():623-42.
1988: D G Sheer; Jeffrey Schlom; H L Cooper
Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3.
Cancer research 1988;48(23):6811-8.
1988: R Tran; Syed V S Kashmiri; Judith A Kantor; John W Greiner; S Pestka; J E Shively; Jeffrey Schlom
Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells.
Cancer research 1988;48(20):5674-9.
1988: David Colcher; M F Minelli; Mario Roselli; Raffaella Muraro; D Simpson-Milenic; Jeffrey Schlom
Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Cancer research 1988;48(16):4597-603.
1988: A Thor; M J Viglione; N Ohuchi; J Simpson; R Steis; J Cousar; Marc Lippman; Donald Kufe; Jeffrey Schlom
Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow.
Breast cancer research and treatment 1988;11(2):133-45.
1988: Jorge Carrasquillo; P Sugarbaker; David Colcher; James C Reynolds; J Esteban; G Bryant; P Perentesis; K Yokoyama; M Rotman; Jeffrey Schlom
Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody.
Radiology 1988;167(1):35-40.
1988: R Tran; P H Hand; John W Greiner; S Pestka; Jeffrey Schlom
Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons.
Journal of interferon research 1988;8(1):75-88.
1988: Fiorella Guadagni; Jeffrey Schlom; S Pothen; S Pestka; John W Greiner
Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon.
Cancer immunology, immunotherapy : CII 1988;26(3):222-30.
1987: N Ohuchi; J F Simpson; D Colcher; Jeffrey Schlom
Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas.
International journal of cancer. Journal international du cancer 1987;40(6):726-33.
1987: N Whittle; J Adair; C Lloyd; L Jenkins; J Devine; Jeffrey Schlom; A Raubitschek; David Colcher; M Bodmer
Expression in COS cells of a mouse-human chimaeric B72.3 antibody.
Protein engineering 1987;1(6):499-505.
1987: D Colcher; J Esteban; Jorge Carrasquillo; P Sugarbaker; James C Reynolds; G Bryant; Steven M Larson; Jeffrey Schlom
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
Cancer research 1987;47(15):4218-24.
1987: N Ohuchi; D Wunderlich; J Fujita; D Colcher; Raffaella Muraro; M Nose; Jeffrey Schlom
Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes.
Cancer research 1987;47(13):3565-71.
1987: P H Hand; V Vilasi; A Thor; N Ohuchi; Jeffrey Schlom
Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Journal of the National Cancer Institute 1987;79(1):59-65.
1987: N Ohuchi; D L Page; M J Merino; M J Viglione; Donald Kufe; Jeffrey Schlom
Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast.
Journal of the National Cancer Institute 1987;79(1):109-17.
1987: J M Esteban; Jeffrey Schlom; F Mornex; D Colcher
Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs.
European journal of cancer & clinical oncology 1987;23(6):643-55.
1987: N Ohuchi; P H Hand; GR Merlo; J Fujita; Renato Mariani-Costantini; A Thor; M Nose; Robert Callahan; Jeffrey Schlom
Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Cancer research 1987;47(5):1413-20.
1987: D Colcher; J M Esteban; Jorge Carrasquillo; P Sugarbaker; James C Reynolds; G Bryant; Steven M Larson; Jeffrey Schlom
Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients.
Cancer research 1987;47(4):1185-9.
1987: J M Esteban; D Colcher; P Sugarbaker; Jorge Carrasquillo; G Bryant; A Thor; J C Reynolds; Steven M Larson; Jeffrey Schlom
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.
International journal of cancer. Journal international du cancer 1987;39(1):50-9.
1987: Raffaella Muraro; D Wunderlich; A Thor; R Cunningham; P Noguchi; Jeffrey Schlom
Immunological characterization of a novel human colon-associated antigen (CAA) by a monoclonal antibody.
International journal of cancer. Journal international du cancer 1987;39(1):34-44.
1987: A Thor; Raffaella Muraro; F Gorstein; N Ohuchi; M Viglione; C A Szpak; W W Johnston; Jeffrey Schlom
Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity.
Cancer research 1987;47(2):505-12.
1987: D Colcher; Jorge Carrasquillo; J M Esteban; P Sugarbaker; James C Reynolds; K Siler; G Bryant; Steven M Larson; Jeffrey Schlom
Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1987;14(3):251-62.
1987: A Thor; M J Viglione; Raffaella Muraro; N Ohuchi; Jeffrey Schlom; F Gorstein
Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1987;6(3):235-47.
1986: A Thor; M O Weeks; Jeffrey Schlom
Monoclonal antibodies and breast cancer.
Seminars in oncology 1986;13(4):393-401.
1986: A Caruso; Jeffrey Schlom; V Vilasi; M O Weeks; P H Hand
Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products.
International journal of cancer. Journal international du cancer 1986;38(4):587-95.
1986: Charles Theillet; R Lidereau; C Escot; P Hutzell; M Brunet; J Gest; Jeffrey Schlom; Robert Callahan
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.
Cancer research 1986;46(9):4776-81.
1986: S E Martin; S Moshiri; A Thor; V Vilasi; E W Chu; Jeffrey Schlom
Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
American journal of clinical pathology 1986;86(1):10-8.
1986: A Thor; F Gorstein; N Ohuchi; C A Szpak; W W Johnston; Jeffrey Schlom
Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
Journal of the National Cancer Institute 1986;76(6):995-1006.
1986: A Thor; N Ohuchi; C A Szpak; W W Johnston; Jeffrey Schlom
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
Cancer research 1986;46(6):3118-24.
1986: N Ohuchi; A Thor; D L Page; P H Hand; S A Halter; Jeffrey Schlom
Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Cancer research 1986;46(5):2511-9.
1985: Raffaella Muraro; D Wunderlich; A Thor; J Lundy; P Noguchi; R Cunningham; Jeffrey Schlom
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues.
Cancer research 1985;45(11 Pt 2):5769-80.
1985: P Horan Hand; D Colcher; D Salomon; J Ridge; P Noguchi; Jeffrey Schlom
Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.
Cancer research 1985;45(2):833-40.
1985: Jeffrey Schlom; D Colcher; P H Hand; J Greiner; D Wunderlich; M Weeks; P B Fisher; P Noguchi; S Pestka; Donald Kufe
Monoclonal antibodies reactive with breast tumor-associated antigens.
Advances in cancer research 1985;43():143-73.
1984: Jeffrey Schlom; J Greiner; P H Hand; D Colcher; G Inghirami; M Weeks; S Pestka; P B Fisher; P Noguchi; Donald Kufe
Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer.
Cancer 1984;54(11 Suppl):2777-94.
1984: A Thor; P Horan Hand; D Wunderlich; A Caruso; Raffaella Muraro; Jeffrey Schlom
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases.
Nature 1984;311(5986):562-5.
1984: John W Greiner; P H Hand; P Noguchi; P B Fisher; S Pestka; Jeffrey Schlom
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.
Cancer research 1984;44(8):3208-14.
1984: P H Hand; A Thor; D Wunderlich; Raffaella Muraro; A Caruso; Jeffrey Schlom
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(16):5227-31.
1984: J L McCoy; A Tagliabue; R E Ames; Y A Teramoto; G B Cannon; C Alford; R B Herberman; Jeffrey Schlom
Indirect leukocyte migration inhibition in breast cancer and benign breast disease patients by mouse mammary tumor virus grown in feline kidney cells.
Journal of the National Cancer Institute 1984;72(3):569-76.
1983: D Colcher; P H Hand; D Wunderlich; M Nuti; Y A Teramoto; Donald Kufe; Jeffrey Schlom
Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy.
Laboratory and research methods in biology and medicine 1983;8():215-58.
1983: P Horan Hand; D Colcher; D Wunderlich; M Nuti; Y A Teramoto; Jeffrey Schlom
Non-HLA antigens in breast cancer.
Progress in clinical and biological research 1983;133():115-24.
1982: Y A Teramoto; R Meriani; D Wunderlich; Jeffrey Schlom
The immunohistochemical reactivity of a human monoclonal antibody with tissue sections of human mammary tumors.
Cancer 1982;50(2):241-9.
1982: M Nuti; Y A Teramoto; Renato Mariani-Costantini; P H Hand; D Colcher; Jeffrey Schlom
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.
International journal of cancer. Journal international du cancer 1982;29(5):539-45.
1981: D Wunderlich; Y A Teramoto; C Alford; Jeffrey Schlom
The use of lymphocytes from axillary lymph nodes of mastectomy patients to generate human monoclonal antibodies.
European journal of cancer & clinical oncology 1981;17(7):719-30.
1981: D Colcher; P Horan Hand; Y A Teramoto; D Wunderlich; Jeffrey Schlom
Use of monoclonal antibodies to define the diversity of mammary tumor viral gene products in virions and mammary tumors of the genus Mus.
Cancer research 1981;41(4):1451-9.
1980: Jeffrey Schlom; D Wunderlich; Y A Teramoto
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(11):6841-5.
1980: Y A Teramoto; P H Hand; R Callahan; Jeffrey Schlom
Detection of novel murine mammary tumor viruses by interspecies immunoassays.
Journal of the National Cancer Institute 1980;64(4):967-75.
1980: P H Hand; Y A Teramoto; R Callahan; Jeffrey Schlom
Interspecies radioimmunoassay for the major internal protein of mammary tumor viruses.
Virology 1980;101(1):61-71.